Sodium-glucose co-transporter-2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP1) receptor agonists, and non-steroidal mineralocorticoid receptor antagonists have recently been shown to have important renoprotective effects in patients with diabetes, which is also paralleled by a significant and important reduction in cardiovascular morbidity and mortality [1,2,3]. Here, SLC5A2 is linked to diabetes mellitus.